2024
Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years
Kostiuk V, Thaxton C, Loh S, Cardella J, Dardik A, Tonnessen B. Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years. JVS-Vascular Insights 2024, 2: 100077. DOI: 10.1016/j.jvsvi.2024.100077.Peer-Reviewed Original ResearchClinical trialsFemale vascular surgeonsVascular surgeonsMethods Clinical trialsArtery diseaseClinical trial leadershipSite principal investigatorsVascular conditionsAbdominal aortic aneurysmSurgeon-investigatorInvestigator-led trialsCarotid artery diseasePeripheral arterial diseaseCarotid diseaseProportion of womenVenous thrombectomyBoard certificationAortic aneurysmPercentage of womenIndustry-sponsored trialsTrial leadershipHemodialysis accessSubgroup analysisVascular surgerySurgeons
2004
Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer
Tonnessen B, Money S. Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer. Perspectives In Vascular Surgery And Endovascular Therapy 2004, 16: 144-146. DOI: 10.1177/153100350401600217.Peer-Reviewed Original ResearchWeight heparin groupRecurrent venous thromboembolismRecurrent thromboembolismVenous thromboembolismWeight heparinAnticoagulation groupHeparin groupOpen-label clinical trialLowmolecular-weight heparinAcute venous thromboembolismOral anticoagulant therapyDeep vein thrombosisGroup of patientsMolecular weight heparinLower mortality rateOral anticoagulantsAnticoagulant therapyPulmonary embolismVein thrombosisCancer patientsClinical trialsEffective therapyThromboembolismMortality ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply